Eloxx Pharmaceuticals, Inc. (ELOX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 70K 140K 210K Q3 '12: 200K Q4 '12: 0 Q3 '12 Q4 '12

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-75M -50M -25M 0 25M 50M 75M Q1 '14: -6.5M Q2 '14: -9.1M Q3 '14: -12.6M Q4 '14: -21.7M Q1 '15: -20.8M Q2 '15: -18.1M Q3 '15: -14M Q4 '15: -7.1M Q1 '16: -10.7M Q2 '16: -11.2M Q3 '16: -12.3M Q4 '16: -10M Q1 '17: -7.7M Q2 '17: -9.5M Q3 '17: -11.3M Q4 '17: -20.4M Q1 '18: -26.3M Q2 '18: -36.7M Q3 '18: -44M Q4 '18: -47.6M Q1 '19: -51M Q2 '19: -51.8M Q3 '19: -53.2M Q4 '19: -50.6M Q1 '20: -52.3M Q2 '20: -45.6M Q3 '20: -39.1M Q4 '20: -33.5M Q1 '21: -28.1M Q2 '21: -56.2M Q3 '21: -60.2M Q4 '21: -66M Q1 '22: -68.6M Q2 '22: -43.1M Q3 '22: -40M Q4 '22: -34.4M Q1 '23: -28.9M Q2 '23: -22.8M Q3 '23: -19.3M Q4 '23: -17.3M Q1 '15 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23

Net Income TTM

-75M -50M -25M 0 25M 50M 75M Q1 '14: -7.5M Q2 '14: -9.2M Q3 '14: -12.6M Q4 '14: -21.8M Q1 '15: -20.8M Q2 '15: -18.1M Q3 '15: -13.1M Q4 '15: -6.2M Q1 '16: -8M Q2 '16: -8.3M Q3 '16: -9M Q4 '16: -6M Q1 '17: -5.6M Q2 '17: -8.3M Q3 '17: -11.4M Q4 '17: -21.2M Q1 '18: -27.1M Q2 '18: -36.6M Q3 '18: -43.8M Q4 '18: -47.2M Q1 '19: -50.5M Q2 '19: -51.6M Q3 '19: -53.3M Q4 '19: -50.9M Q1 '20: -52.9M Q2 '20: -46.3M Q3 '20: -40.1M Q4 '20: -34.6M Q1 '21: -29.3M Q2 '21: -57.5M Q3 '21: -60.8M Q4 '21: -66.7M Q1 '22: -69.7M Q2 '22: -44.2M Q3 '22: -41.8M Q4 '22: -36.1M Q1 '23: -30.7M Q2 '23: -24.4M Q3 '23: -20.5M Q4 '23: -17.1M Q1 '15 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q1 '14: -4.6M Q2 '14: -4.9M Q3 '14: -6.1M Q4 '14: -6.2M Q1 '15: -6.1M Q2 '15: -7.3M Q3 '15: -6.5M Q4 '15: -6M Q1 '16: -5.4M Q2 '16: -3.7M Q3 '16: -3.1M Q4 '16: -2.6M Q1 '17: -4.5M Q2 '17: -6.9M Q3 '17: -6.9M Q4 '17: -177.3K Q1 '18: -3.1M Q2 '18: -8.5M Q3 '18: -16M Q4 '18: -31.4M Q1 '19: -34.9M Q2 '19: -36M Q3 '19: -39.2M Q4 '19: -39.4M Q1 '20: -42.1M Q2 '20: -38.8M Q3 '20: -32.8M Q4 '20: -28.2M Q1 '21: -23.9M Q2 '21: -27.4M Q3 '21: -29.7M Q4 '21: -35M Q1 '22: -36.8M Q2 '22: -36.8M Q3 '22: -36.1M Q4 '22: -31.8M Q1 '23: -29.2M Q2 '23: -21.5M Q3 '23: -18M Q4 '23: -14.3M Q1 '15 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23

Free Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q2 '11: -5.4M Q3 '12: -3.9M Q4 '12: -3.3M Q1 '13: -4.1M Q2 '13: -3.9M Q3 '13: -3.9M Q4 '13: -4.8M Q1 '14: -4.6M Q2 '14: -4.9M Q3 '14: -6.2M Q4 '14: -6.4M Q1 '15: -6.3M Q2 '15: -7.5M Q3 '15: -6.6M Q4 '15: -6M Q1 '16: -5.4M Q2 '16: -3.7M Q4 '17: -414.3K Q1 '18: -3.4M Q2 '18: -8.7M Q3 '18: -16.2M Q4 '18: -31.6M Q1 '19: -35.1M Q2 '19: -36.1M Q3 '19: -39.3M Q4 '19: -39.4M Q3 '22: -36.2M Q4 '22: -31.9M Q1 '23: -29.2M Q2 '23: -21.5M Q3 '23: -18M Q4 '12 Q4 '13 Q4 '14 Q4 '15 Q1 '18 Q1 '19 Q3 '22 Q3 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '21: 66.4M Q3 '21: 86.2M Q1 '22: 2.2M Q2 '22: 2.2M Q3 '22: 2.2M Q1 '23: 2.2M Q2 '23: 2.2M Q3 '23: 2.7M Q1 '25: 3.8M Q2 '25: 347K Q1 '26: 48.2M Q2 '26: 6.8M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q1 '14: -3.18 Q2 '14: -2.45 Q3 '14: -2.05 Q4 '14: -2.35 Q1 '15: -1.57 Q2 '15: -1.32 Q3 '15: -0.96 Q4 '15: -0.37 Q1 '16: -0.43 Q2 '16: -0.42 Q3 '16: -0.45 Q4 '16: -0.30 Q1 '17: -0.88 Q2 '17: -1.86 Q3 '17: -2.96 Q4 '17: -4.75 Q1 '18: -4.33 Q2 '18: -3.71 Q3 '18: -2.88 Q4 '18: -1.45 Q1 '19: -1.47 Q2 '19: -1.45 Q3 '19: -1.45 Q4 '19: -1.34 Q1 '20: -1.36 Q2 '20: -1.16 Q3 '20: -1.00 Q4 '20: -0.86 Q1 '21: -0.73 Q2 '21: -1.07 Q3 '21: -1.02 Q4 '21: -38.17 Q1 '22: -43.31 Q2 '22: -47.67 Q3 '22: -51.03 Q4 '22: -16.65 Q1 '23: -14.17 Q2 '23: -11.23 Q3 '23: -9.07 Q4 '23: -6.82 Q1 '15 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.